New research from Rhode Island Hospital found that obesity and Type 2 Diabetes Mellitus (T2DM) can contribute to mild neurodegeneration with features common with Alzheimer’s disease (AD) - the first study to show that obesity can cause neurodegeneration. The study appeared in the Journal of Alzheimer’s Disease Volume 15:1 (September 2008) .
More: continued here
EMEA Releases Guidelines On Development Of Medicines For Alzheimer’s Disease And Parkinson’s Disease
The European Medicines Agency (EMEA) has released two guidelines for companies developing medicines for the treatment of Alzheimer’s disease and other dementias, and for Parkinson’s disease, in the light of recent scientific progress in the understanding of these diseases and conditions. Advances in clinical science, physiopathology and molecular biology have stimulated new interest in the development of more effective symptomatic or disease-modifying treatments, i.e.
More: continued here
Dr. Forrest Scogin , an expert in mental health and aging and professor of clinical psychology at The University of Alabama, has won the M. Powell Lawton Distinguished Contribution Award for Applied Gerontology from the American Psychological Association. The award was given at the APA’s convention last month in Boston.
More: continued here
In a collaborative study at the University of California, San Diego, investigators from neurosciences, chemistry and medicine, as well as the San Diego Supercomputer Center (SDSC) have investigated how proteins involved in neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease interact to form unique complexes. Their findings explain why Alzheimer’s patients might develop Parkinson’s, and vice versa.
More: continued here
Regular exercise is one of the best ways to reduce your risk of dementia and can help slow progression of the condition. This study demonstrates that exercise improves cognition in people with Mild Cognitive Impairment, and that there is a lasting effect even after the exercise intervention stops. Mild Cognitive Impairment is a term used to describe someone who has mild memory problems that are not serious enough to interfere with every day life.
More: continued here
Anavex Life Sciences Corp. (”ANAVEX”) (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, announced the successful completion of preclinical studies (in-vitro and in-vivo in mice) on ANAVEX 2-73, a novel sigma-1 receptor agonist for the treatment of Alzheimer’s disease.
More: continued here
Treatment of hypertension has proven to reduce cardiovascular risk substantially, but a large proportion of people with hypertension in the general population are not even diagnosed or treated. As a risk factor for stroke, ischemic brain lesions and silent brain infarcts, general atherosclerosis, myocardial infarction and cardiovascular morbidity, hypertension may also be a risk factor for dementia related to cerebrovascular disease.
More: continued here
As Scotland’s review of the impact of recent changes to mental health legislation gears up, the Mental Welfare Commission for Scotland will be raising awareness of the impact of the legislation on older people at two major conferences this week. ‘Five years after the mental health act’ on September 2nd, will examine the progress that has been made towards delivering the intentions of the first major overhaul of Scottish mental health legislation in fifty years.
More: continued here
A study published in the September 3 issue of JAMA reports that cognitive function modestly improved in adults suffering with memory problems who participated in a home-based physical activity program compared to those who did not participate in the program. Alzheimer disease (AD) affects 26.6 million people worldwide and is expected to affect 106.2 million by 2050 as the world population increases. Nicola T. Lautenschlager, M.D.
More: continued here
Bradford Dementia Group at the University of Bradford leads the way in developing a standard in Dementia Care. On 18 August 2008, members of the Bradford Dementia Group and staff from the British Standards Institution (BSI) launched a project to develop a Publicly Available Specification (PAS) in dementia care.
More: continued here





